European Symposium on Controlled Drug Delivery. Noordwijk aan Zee (NLD), 1996/04/03.
In recent years the health care industry increasingly has been charged with establishing the economic « value » of new pharmaceutical products.
Controlled-release dosage forms have a significant potential to provide economic value by enhancing efficacy and decreasing treatment costs.
In this article we review basic pharmacoeconomic concepts as they apply to controlled-release dosage forms, give an overview of strategies for economic assessment of new drug therapies, summarize selected published stidies that have evaluated the cost effectiveness of controlled-release products, and present examples of three types of pharmacoeconomic analyses that have been considered recently at ALZA Corporation.
We conclude by noting the particular value provided by obtaining timely information about a product's costs. benefits and relative cost-effectiveness from prospective clinicoeconomic studies.
Mots-clés Pascal : Forme pharmaceutique, Forme libération contrôlée, Economie santé, Analyse coût efficacité, Qualité vie, Essai clinique, Technologie pharmaceutique
Mots-clés Pascal anglais : Dosage form, Controlled release form, Health economy, Cost efficiency analysis, Quality of life, Clinical trial, Pharmaceutical technology
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0550050
Code Inist : 002B02A03. Création : 24/03/1998.